IRON MODULATORS

摘要

Iron modulator compounds of formula (I) are provided for treating amyloidoses wherein R<SUP>1</SUP> is selected from H, C<SUB>1-6</SUB> alkyl, C<SUB>1-6</SUB> alkenyl, C<SUB>1-6</SUB> hydroxyalkyl, C<SUB>1-6</SUB> hydroxyalkenyl, R<SUP>2</SUP> is selected from H, C<SUB>1-6</SUB> alkyl, C<SUB>1-6</SUB> alkenyl, C<SUB>1-6</SUB> hydroxyalkyl, C<SUB>1-6 </SUB>hydroxyalkenyl and C<SUB>6-10</SUB> aralykyl in which the aryl group of the aralkyl group is optionally substituted by hydroxy, halo or C1-4 alkyl R<SUP>3</SUP> is selected from H, C<SUB>1-6</SUB> alkyl, C<SUB>1-6</SUB> alkenyl and C<SUB>1-12 </SUB>acyl; R<SUP>4</SUP> is selected from H and C<SUB>1-3 </SUB>alkyl R<SUP>5</SUP>, R<SUP>6</SUP> and R<SUP>7</SUP> are independently selected from H, C<SUB>1-6</SUB> alkyl, C<SUB>3-7</SUB> aryl, and C<SUB>1-10</SUB> aralkyl; the alkyl, aryl and aralkyl groups being optionally substituted by one or more halo, hydroxy and nitro groups or R<SUP>5</SUP> and R<SUP>7</SUP> together with the nitrogen atom to which they are bonded form a heterocyclic ring optionally substituted by one or more hydroxyl groups or a pharmaceutically acceptable tautomer, ester or addition salt thereof.